Literature DB >> 27364636

[Visual acuity in anti-VEGF therapy for AMD : Can specific characteristics in the SD-OCT help?]

B Book1, M Ziegler1, B Heimes1, M Gutfleisch1, G Spital1, D Pauleikhoff2, A Lommatzsch1.   

Abstract

BACKGROUND: The efficacy of anti-VEGF therapy in exudative AMD has been established in several large clinical trials using a fixed injection regimen as well as a SD-OCT-based PRN regimen. In these studies, after the first three injections, an increase of the mean visual acuity was observed, which could be stabilized with constant treatment for up to 24 months. However, the specific course of the visual acuity is very different between individuals. The aim of the present study was to correlate specific initial SD-OCT parameters with the course of visual acuity in order to characterize factors that may be important for the individual visual prognosis. PATIENTS AND METHODS: In a prospective case study, the visual course and SD-OCT changes of 156 patients with minimum follow-up of 12 months (mean 80.1 months) were analysed. Visual acuity (LogMar) was investigated at regular intervals and correlated with specific SD-OCT parameters (foveal thickness, height of sub-retinal fluid or presence of associated PED, presence of intra-retinal cysts, length of IS/OS break, choroidal thickness).
RESULTS: The initial increase in visual acuity could be stabilized over time. This effect was associated with a decrease in foveal retinal thickness, which also persisted over time. While sub-retinal fluid, presence of PED, and choroidal thickness showed no prognostic relevance for the change in visual acuity, the presence of more advanced central retinal thickness, of intra-retinal cysts or a longer break in the IS/OS junction were associated with a less favourable development of visual acuity.
CONCLUSION: In the present study, the presence of more advanced central retinal thickness, of intra-retinal cysts or a larger IS/OS break correlated significantly with a worse visual prognosis. These might be clinical signs for more extensive pre-existing intra-retinal changes. Further analysis and new diagnostic tools may prove this and may result in specific additive neuroprotective or regenerative therapeutic approaches in exudative AMD.

Entities:  

Keywords:  Anti-VEGF therapy; Exudative AMD; Prognostic factor; SD-OCT; Visual acuity

Mesh:

Substances:

Year:  2017        PMID: 27364636     DOI: 10.1007/s00347-016-0308-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  28 in total

1.  [Anti-VEGF therapy of exudative AMD: Prognostic factors for therapy success].

Authors:  B Heimes; A Lommatzsch; M Zeimer; M Gutfleisch; G Spital; D Pauleikhoff
Journal:  Ophthalmologe       Date:  2011-02       Impact factor: 1.059

2.  Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome.

Authors:  Heinrich Gerding; Vlassios Loukopoulos; Juliane Riese; Lars Hefner; Melanie Timmermann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-09       Impact factor: 3.117

3.  Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Authors:  David M Brown; Peter K Kaiser; Mark Michels; Gisele Soubrane; Jeffrey S Heier; Robert Y Kim; Judy P Sy; Susan Schneider
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

4.  Subjective and functional deterioration in recurrences of neovascular AMD are often preceded by morphologic changes in optic coherence tomography.

Authors:  Robert Hoerster; Philipp S Muether; Manuel M Hermann; Konrad Koch; Bernd Kirchhof; Sascha Fauser
Journal:  Br J Ophthalmol       Date:  2011-07-18       Impact factor: 4.638

5.  Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.

Authors:  Frank G Holz; Winfried Amoaku; Juan Donate; Robyn H Guymer; Ulrich Kellner; Reinier O Schlingemann; Andreas Weichselberger; Giovanni Staurenghi
Journal:  Ophthalmology       Date:  2011-04       Impact factor: 12.079

6.  Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT).

Authors:  Gui-shuang Ying; Maureen G Maguire; Ebenezer Daniel; Frederick L Ferris; Glenn J Jaffe; Juan E Grunwald; Cynthia A Toth; Jiayan Huang; Daniel F Martin
Journal:  Ophthalmology       Date:  2015-09-15       Impact factor: 12.079

7.  Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Authors:  Gui-shuang Ying; Jiayan Huang; Maureen G Maguire; Glenn J Jaffe; Juan E Grunwald; Cynthia Toth; Ebenezer Daniel; Michael Klein; Dante Pieramici; John Wells; Daniel F Martin
Journal:  Ophthalmology       Date:  2012-10-06       Impact factor: 12.079

8.  Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

Authors:  Jeffrey S Heier; David M Brown; Victor Chong; Jean-Francois Korobelnik; Peter K Kaiser; Quan Dong Nguyen; Bernd Kirchhof; Allen Ho; Yuichiro Ogura; George D Yancopoulos; Neil Stahl; Robert Vitti; Alyson J Berliner; Yuhwen Soo; Majid Anderesi; Georg Groetzbach; Bernd Sommerauer; Rupert Sandbrink; Christian Simader; Ursula Schmidt-Erfurth
Journal:  Ophthalmology       Date:  2012-10-17       Impact factor: 12.079

9.  Foveal morphology affects self-perceived visual function and treatment response in neovascular age-related macular degeneration: a cohort study.

Authors:  Yousif Subhi; Gitte Ø Henningsen; Charlotte T Larsen; Mette S Sørensen; Torben L Sørensen
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

10.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves
Journal:  Ophthalmology       Date:  2012-05-11       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.